... Doctors Can Now Target the TROP2 ProteinIn June 2025, the FDA approved datopotamab deruxtecan-dlnk (Datroway) for EGFR-mutant NSCLC that no longer responds to prior treatments. This drug targets the TROP2 protein and delivers chemotherapy directly to cancer cells. ...
Biomarkers for Lung Cancer: 12 Things To Know
... Doctors Can Now Target the TROP2 ProteinIn June 2025, the FDA approved datopotamab deruxtecan-dlnk (Datroway) for EGFR-mutant NSCLC that no longer responds to prior treatments. This drug targets the TROP2 protein and delivers chemotherapy directly to cancer cells. ...